Composition for Treating Spermatogenesis and Semen Disorders / FPT-20

• Status: Completed
• Trial end date: 2022-05-20
• Target enrollment: 0
• Participant gender: Male

Summary

Research to develop a new, natural-derived formulation that eliminates inflammatory tissue and regenerates new tissue of the lobules, epithelium of the tubules, and connective tissue surrounding the seminiferous tubules in the testes. It restores Leydig cells and Sertoli cells' function (because the inflamed testicles were unable to perform spermatogenesis).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Trieu, Nguyen Thi, M.D.
• Collaborator: Tran Minh Duc

Criteria

Inclusion Criteria:

• The selected person has evidence of spermatogenesis disorder, no sperm, and weak sperm that do not meet the standards in terms of quantity and quality.

• There are signs of orchitis.

• Accepting patients with other comorbidities such as metabolic diseases, congenital or acquired immunodeficiency, HIV/AIDS, HBV, HCV, and Tuberculosis.

Exclusion Criteria:

• Do not select patients with advanced cancer.